Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.

PloS one - 1 Jan 2012

Zander Serge A L, Sol Wendy, Greenberger Lee, Zhang Yixian, van Tellingen Olaf, Jonkers Jos, Borst Piet, Rottenberg Sven

Abstract excerpt

BRCA1 dysfunction in hereditary breast cancer causes defective homology-directed DNA repair and sensitivity towards DNA damaging agents like the clinically used topoisomerase I inhibitors topotecan and irinotecan. Using our conditional K14cre;Brca1(F/F);p53(F/F) mouse model, we showed previously...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine
Share to ATP Binding Cassette Transporter, Subfamily G, Member 2
Share to DNA Topoisomerases, Type I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterocyclic Compounds, 4 or More Rings

Share to Irinotecan

Share to Mammary Glands, Animal

Share to Mammary Neoplasms, Animal

Share to Topoisomerase I Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 23028879
DOI: 10.1371/journal.pone.0045248
PMCID: PMC3444454

Genes

ABCG2
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23028879-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.PMID 23028879Read ↗

Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor TopotecanSemantic proximity Read ↗

Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.Semantic proximity Read ↗

ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to ChemotherapySemantic proximity Read ↗

BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug ResistanceSemantic proximity Read ↗

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancerSemantic proximity Read ↗

HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab DeruxtecanSemantic proximity Read ↗

Topoisomerase levels determine chemotherapy response <i>in vitro</i> and <i>in vivo</i>Semantic proximity Read ↗

Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast CancerSemantic proximity Read ↗

Drug resistance in the mouse cancer clinicSemantic proximity Read ↗

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.Semantic proximity Read ↗

A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.Semantic proximity Read ↗

Thiosemicarbazone T2 suppresses WNT/β-catenin signaling and limits progression to invasive disease in a mouse intraductal model of triple-negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.